Sigyn Therapeutics Inc Net Income per Employee (RSAP), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Sigyn Therapeutics Inc   (RSAP)
 

Sigyn Therapeutics Inc Net Income per Employee

RSAP's Quarterly Results, Trends, Rankings, Statistics
Sigyn Therapeutics Inc recorded a cumulative net loss of $-3 million during 12 month ending in the third quarter 2025.
The Healthcare sector has seen employees of 139 other companies achieving higher income per employee. While Sigyn Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 2782 to 3254.


What is Income per Employee Ratio?






RSAP Net Income per Employee (Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -230,077 -274,249 -232,192 -238,587 -285,246
RSAP's Total Ranking # 3254 # 2782 # 3064 # 0 # 3077
Seq. Net Income Change - - - - -


RSAP Net Income per Employee Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 140
Healthcare Sector # 373
Overall Market # 3254

Net Income per Employee Statistics
High Average Low
$ 30,842 $ -209,974 $ -312,626
(Sep 30 2017)   (Mar 31 2018)







Companies with similar Income per Employee for 12 month ending Sep 30 2025, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2025Number of Employees Sep 30 2025


Date modified: 2026-09-08T15:11:35+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.